title: Depot risperidone-induced adverse metabolic alterations in female rats.
abstract: Atypical antipsychotics are associated with adverse metabolic effects including weight gain, increased adiposity, dyslipidaemia, alterations in glucose metabolism and insulin resistance. Increasing evidence suggests that metabolic dysregulation precedes weight gain development. The aim of this study was to evaluate alterations in adipokines, hormones and basic serum biochemical parameters induced by chronic treatment with depot risperidone at two doses (20 and 40 mg/kg) in female Sprague-Dawley rats. Dose-dependent metabolic alterations induced by risperidone after 6 weeks of treatment were revealed. Concomitant to weight gain and increased liver weight, an adverse lipid profile with an elevated triglyceride level was observed in the high exposure group, administered a 40 mg/kg dose repeatedly, while the low dose exposure group, administered a 20 mg/kg dose, developed weight gain without alterations in the lipid profile and adipokine levels. An initial peak in leptin serum level after the higher dose was observed in the absence of weight gain. This finding may indicate that the metabolic alterations observed in this study are not consequent to body weight gain. Taken together, these data may support the primary effects of atypical antipsychotics on peripheral tissues.
authors.affiliation: 1 Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic.
authors.forename: Katerina
authors.initials: K
authors.lastname: Horska
authors.affiliation: 2 Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
authors.forename: Jana
authors.initials: J
authors.lastname: Ruda-Kucerova
authors.affiliation: 1 Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic.|3 R&D Department, Biovendor - Laboratorni Medicina, Brno, Czech Republic.
authors.forename: Michal
authors.initials: M
authors.lastname: Karpisek
authors.affiliation: 1 Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic.
authors.forename: Pavel
authors.initials: P
authors.lastname: Suchy
authors.affiliation: 4 Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic.
authors.forename: Radka
authors.initials: R
authors.lastname: Opatrilova
authors.affiliation: 1 Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic.
authors.forename: Hana
authors.initials: H
authors.lastname: Kotolova
mesh_terms: D054392:Adipokines / Q000378:metabolism; D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects*; D005260:Female; D020738:Leptin / Q000378:metabolism; D008055:Lipids; D051381:Rats; D017207:Rats, Sprague-Dawley; D018967:Risperidone / Q000009:adverse effects*; D015430:Weight Gain / Q000187:drug effects
chemical_list: D054392:Adipokines; D014150:Antipsychotic Agents; D020738:Leptin; D008055:Lipids; D018967:Risperidone
keywords: Adipokine; Sprague−Dawley rats; depot risperidone; leptin; lipid profile